Vivere Lifesciences Acquisition Corp.’s HK Listing

Allen & Overy and Harneys acted for Vivere Lifesciences Acquisition Corp.

On 21 February, 2022, Vivere Lifesciences Acquisition Corporation submitted its listing application for the Main Board of the Hong Kong Stock Exchange. 

UBS Securities Hong Kong Limited acted as Sole Sponsor. 

Vivere Lifesciences is looking to collaborate with target companies focused on healthcare and biotechnology in China. 

The team advising on the transaction was led by the Head of Allen & Overy’s Hong Kong corporate team, partner Lina Lee, with support from Ryan Tou (Counsel) and Michelle Tsang (Associate), with US securities support from Alex Stathopoulos (Partner).

The Harneys team was led by Shanghai Corporate Partner Calamus Huang (Picture) and Counsel Jessie Xu. 

Involved fees earner: Lina Lee – Allen & Overy; Alex Stathopoulos – Allen & Overy; Ryan Tou – Allen & Overy; Michelle Tsang – Allen & Overy; Calamus Huang – Harneys; Jessie Xu – Harneys;

Law Firms: Allen & Overy; Harneys;

Clients: Vivere Lifesciences Acquisition Corp.;

Sonia Carcano

Author: Sonia Carcano